Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-25-000629
Filing Date
2025-04-14
Accepted
2025-04-14 14:09:39
Documents
71
Period of Report
2025-02-28

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q lxrp_10q.htm   iXBRL 10-Q 952026
2 FORM OF DIRECTOR SERVICES AGREEMENT lxrp_ex103.htm EX-10.3 33917
3 CERTIFICATION lxrp_ex311.htm EX-31.1 12037
4 CERTIFICATION lxrp_ex312.htm EX-31.2 12548
5 CERTIFICATION lxrp_ex321.htm EX-32.1 6433
6 CERTIFICATION lxrp_ex322.htm EX-32.2 6573
  Complete submission text file 0001640334-25-000629.txt   5110785

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20250228.xsd EX-101.SCH 50974
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20250228_lab.xml EX-101.LAB 289402
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20250228_cal.xml EX-101.CAL 46567
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20250228_pre.xml EX-101.PRE 242735
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20250228_def.xml EX-101.DEF 126160
74 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_10q_htm.xml XML 836203
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 001-39874 | Film No.: 25835417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)